DivestmentJul 30, 2026, 04:09 PM
NEOGEN to Divest Genomics Business to Zoetis for $160M
AI Summary
NEOGEN Corporation announced the planned divestment of its Genomics business to Zoetis Inc. for $160.0 million, with the transaction currently undergoing regulatory review. This follows the divestment of its global Cleaners and Disinfectants business in July 2025. The company also reported that international sales contributed significantly, accounting for 51.2% of total revenues in fiscal year 2026.
Key Highlights
- NEOGEN to divest Genomics business to Zoetis Inc. for $160.0 million.
- Transaction is subject to regulatory approvals, with ACCC and NZCC in second phase review.
- Divested global Cleaners and Disinfectants business in July 2025.
- International sales accounted for 51.2% of total revenues in fiscal year 2026.
- R&D expenditure is projected to be 2% to 5% of total revenues annually.
- Royalties for licensed technology totaled $1.9 million in fiscal year 2026.
Price Impact
More from NEOG
Quarterly Result13h ago
Neogen Q4 Revenue $225.3M, Core Growth 4.3%; FY27 Guidance
Quarterly ResultApr 9, 4:07 PM
NEOGEN CORP Files Q3 2026 Quarterly Report, Reports 217.7M Shares Outstanding
Quarterly ResultApr 9, 7:06 AM
Neogen Reports Q3 FY2026 Revenue of $211.2M, GAAP EPS of $(0.08) Amidst Animal Safety Supplier Challenges